Alzamend Neuro, Inc. ALZN
1.53 USD +0.07 (+4.79%)
At closeNov 4, 2026, 4:33 PM EST
1.57 +0.04 +2.61%
After hours · Nov 4, 4:33 PM ET
1.48 Day range 1.62
0.84 52-week range 2.61
- YTD
- -15.93%
- 1 year
- -39.04%
News
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
zacks.com Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? Alzamend Neuro (ALZN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
benzinga.com Alzamend Neuro Regains Nasdaq Compliance Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
benzinga.com Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.56) by 21.43 percent. This is a 46.88 percent increase over losses of…
benzinga.com Alzamend Neuro Announces Its Abstract On Resting-State Functional Magnetic Resonance Imaging Findings For AL001 Accepted For Presentation At Neuroscience 2026 Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
prnewswire.com Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026 in Washington, DC Presentation Title: Assessing Treatment-Associated Brain Network Changes…
benzinga.com Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts changed outlook on top names. Piper Sandler raises Mercury Systems' target price, Ascendiant Capital boosts Alzamend Neuro's target price, BTIG raises Henry Schein's target price, Cantor…
benzinga.com Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26 Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and raises the price target from $25 to $26.- benzinga.com Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, SpainPresentation will…
prnewswire.com Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will…
benzinga.com Alzamend Neuro Signs $25M Securities Purchase Agreement With Ault Lending; Alzamend Receives $7.5M In Gross Proceeds Form Initial Tranche Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
prnewswire.com Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.0 million. Catheter Precision…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. Atlantic International…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ:VVOS) shares…- benzinga.com Alzamend Neuro Announces Pharmacodynamic Findings From Brain Magnetic Resonance Spectroscopy Analysis Conducted In Healthy Human Subjects In Trial Conducted At Massachusetts General Hospital Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact…
prnewswire.com Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Alzamend Announces Topline Data From First Phase II "Lithium In Brain" Clinical Trial, Demonstrating AL001 Meets Bioequivalence Standards, And Showing Numerically Superior Lithium Delivery To Brain Compared To Standard Lithium Carbonate Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonateSuperior Brain Penetration: AL001 showed numerically higher…
prnewswire.com Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonate Superior Brain Penetration: AL001 showed numerically…- benzinga.com Alzamend Neuro Starts Phase II Clinical Study Of AL001 In Participants With Bipolar Disorder Type 1; Topline Data Anticipated By March End Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar…
prnewswire.com Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain/brain-structure pharmacokinetics in bipolar disorder type 1 patients Topline data expected in…- benzinga.com 10 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
defenseworld.net Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell? Shares of Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) dropped 2.5% on Monday. The stock traded as low as $2.20 and last traded at $2.33. Approximately 43,364 shares were traded during…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $28 Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $42 to $28.- benzinga.com Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(1.96) by 84.65 percent. This is a 91.69 percent increase over losses of…
defenseworld.net Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 0.5% – Here’s Why Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) shares were down 0.5% on Friday. The company traded as low as $1.95 and last traded at $1.96. Approximately 72,560 shares changed hands during…
prnewswire.com Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital Topline data expected in first quarter of 2026 Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure…
benzinga.com EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.- benzinga.com Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $42 Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ: ALZN) with a Buy and lowers the price target from $45 to $42.
benzinga.com Alzamend Neuro Q1 EPS $(1.28) Misses $(0.69) Estimate Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.69) by 85.51 percent. This is a 88.79 percent increase over losses of…
benzinga.com Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday 
benzinga.com Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $45 Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $180 to $45.
globenewswire.com Alzamend Neuro to Present at the 2025 Military Health System Research Symposium Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD…
globenewswire.com Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025,…
globenewswire.com Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
globenewswire.com Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure…
globenewswire.com Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure…
globenewswire.com Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure…
globenewswire.com Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA,…
zacks.com Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? After losing some value lately, a hammer chart pattern has been formed for Alzamend Neuro (ALZN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate…
globenewswire.com Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of…